Femasys is trading 10.23% lower at $1.58, with no clear company-specific news explaining the decline; broader risk-off pressure is a more plausible factor. - Supplied market context cites hotter-than-forecast annual CPI, rising yields and major indexes lower. - Biotech was weak, with XBI down 2.01%; these are supporting context, not confirmed direct causes. - On October 14, Femasys said it doubled actively enrolling FemBloc pivotal-trial sites to twelve, a progress update rather than an evident negative catalyst.